Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (191-200 of 254) with videos related to

Pageof 26
Sort By:
Journal of Crohn'S & Colitis|February 10, 2022
Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's DiseaseMarjolaine Ngollo, Kevin Perez, Nassim Hammoudi, et al.
Therapeutic Advances in Gastroenterology|August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAIDBénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained RemissionCatherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort studyAurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort studyMathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Pageof 26

Showing results (191-200 of 254) with videos related to

Sort By:
Pageof 26
Journal of Crohn'S & Colitis|February 10, 2022
Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's DiseaseMarjolaine Ngollo, Kevin Perez, Nassim Hammoudi, et al.
Therapeutic Advances in Gastroenterology|August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAIDBénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained RemissionCatherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort studyAurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort studyMathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|February 26, 2022
Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective CohortClément Julien, Emré Anakok, Xavier Treton, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative ColitisMathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Pageof 26